ILL Effects of Tuberculosis Drugs: No More a Problem

Abstract:

Facilitating the alteration of the pharmacokinetics and pharmacodynamics of variety of drugs, nanoparticles are sort of particulate systems with the potential to minimize their ill-effects and increase the therapeutic benefit of the drug molecules in the human body. These particles deliver the drug at a specific target and help to keep the drug intact in the systemic circulation. According to previous studies, drug delivery system via nanoparticles has application in treatment of tuberculosis. With the understanding of chemotherapy in tuberculosis, the article highlights the considerable potential of nanoparticles in the treatment for MDR tuberculosis. We would also like discuss briefly on nanoDN`A-Biosensors through this article.

• Periodical: Applied Mechanics and Materials (Volumes 110-116)
• Pages: 2015-2019
• DOI: https://doi.org/10.4028/www.scientific.net/AMM.110-116.2015
• Online since: October 2011
• Authors: Aishvarya Aishvarya, Vidhi Gupta, Man Preet, Kushagr Punyani
• Keywords: Anti-TB Drugs, Drug Delivery, MDR Tuberculosis, Nano DNA-Biosensors, Nanoparticle, Targeting

References

[1] Melvern, Nanotechnology Solutions, Innovative Solutions in MaterialCharacterization. http: /www. malvern. com, accessed on 21st August, (2010).

[2] S. Gelperina, K. Kisich, D. Michael, Iseman, and L. Heifets, The Potential Advantages of Nanoparticle Drug Delivery Systems in Chemotherapy of Tuberculosis, m Am J Respir Crit Care Med Vol 172. p.1487–1490, (2005).

DOI: 10.1164/rccm.200504-613pp

[3] J. Prasad, Mathuria, Nanoparticles in Tuberculosis Diagnosis, Treatment and Prevention: A hope for future, Digest Journal of Nanomaterials and Biostructures Vol. 4. No. 2, p.309 – 312, (2009).

[4] Justo OR, AM. Moraes, Kanamycin incorporation in lipid vesicles prepared by ethanol injection designed for tuberculosis treatment,. J Pharm Pharmacol; Vol. 57. pp.23-30, (2005).

DOI: 10.1211/0022357055092

[5] JM. Irache, M. Merodio, A. Arnedo, MA. Camapanero, M. Mirshahi, S. Espuelas, Albumin nanoparticles for the intravitreal delivery of anticytomegaloviral drugs, Mini Rev Med Chem Vol. 5. pp.293-305, (2005).

DOI: 10.2174/1389557053175335

[6] RB. Umamaheshwari, S. Ramteke, N.K. Jain, Anti-Helicobacter pylori effect of mucoadhesive nanoparticles bearing amoxicillin in experimental gerbils model, AAPS Pharm Sci Tech Vol. 5. e32, (2004).

DOI: 10.1208/pt050232

[7] R. Pandey, Z. Ahmad, S. Sharma, G.K. Khuller, Nanoencapsulation of azole antifungals: potential applications to improve oral drug delivery, Int J Pharm 2005; 301: 268-76.

DOI: 10.1016/j.ijpharm.2005.05.027

[8] R.M. Lucinda-Silva, R.C. Evangelista, Microspheres of alginatechitosan containing isoniazid, J Micropencasul Vol. 20. pp.145-52, (2003).

[9] G.K. Khuller, M. Kapur, S. Sharma, Liposome technology for drug delivery against mycobacterial infections, Curr Pharm Des Vol. 10. No. 32 pp.63-74, (2004).

DOI: 10.2174/1381612043383250

[10] Q. Ain, S. Sharma, G.K. Khuller, S.K. Garg, Alginatebased oral drug delivery system for tuberculosis: pharmacokinetics and therapeutic effects, J Antimicrob Chemother; Vol 51. pp.931-8, (2003).

[11] R. Pandey, G.K. Khuller,. Chemotherapeutic potential of alginatechitosan microspheres as antitubercular drug carriers, J Antimicrob Chemother; Vol 53. pp.635-40, (2004).

[12] K.C. Stone, R.R. Mercer., P. Gehr., B. Stockstill, J.D. Capro, Allometric relationships of cell numbers and size in the mammalian lung, Am. J. Respir. Cell Mol. Biol.; Vol 6. pp.235-243, (1992).

DOI: 10.1165/ajrcmb/6.2.235

[13] Gehr P. The normal human lung: ultrastructure and morphometric estimations of diffusion capacity. Physiol.; Vol 32. pp.121-140, (1978).

DOI: 10.1016/0034-5687(78)90104-4

[14] C. Jacobs & R. H. Muller, Production and characterization of a budesonide nanosuspension for pulmonary administration, Pharmaceutical Research.; Vol. 19, p.189–94, (2002).

[15] R. A. Jain, The manufacturing techniques of various drug loaded biodegradable poly (lactide-co-glycolide) (PLGA) devices,. Biomaterials; Vol. 21. p.2475–90, (2000).

DOI: 10.1016/s0142-9612(00)00115-0

[16] I. Bala, S. Hariharan, & M. N. V. R. Kumar, PLGA nanoparticles in drug delivery: the state of the art. Critical Reviews in Therapeutic Drug Carrier Systems, Vol. 21. p.387–422, (2004).

DOI: 10.1615/critrevtherdrugcarriersyst.v21.i5.20

[17] A. Lamprecht, N. Ubrich, P. Hombreiro, et al. Biodegradable monodispersed nanoparticles prepared by pressure homogenizationemulsification, International Journal of Pharmaceutics; Vol. 184, p.97–105, (1999).

DOI: 10.1016/s0378-5173(99)00107-6

[18] J. Crofton, P. Chaulet, D. Maher, Guidelines for the management of drug resistant tuberculosis, WHO/ TB/ 96. 210 Rev (1), (1997).

[19] R. Singh, D. Gothi, J.M. Joshi, Multidrug resistant tuberculosis: role of previous treatment with second line therapy on treatment outcome. Lung India,; Vol. 24. pp.54-57, (2007).

DOI: 10.4103/0970-2113.44211

[20] R.F. Taylor, and J.S. Schultz,. Handbook of Chemical and Biological Sensors,. Institute of Physics Publishing, Bristol, UK, (1996).

[21] T.K. Christopoulos, Anal. Chem,.; 71, 425R-438R, (1999).

[22] E. Palecek, M. Fojta, M. Tomschick, and J. Wang, Biosens. Bioelectron,; 13, 621-628, (1998).

[23] J. Zhai, C. Hong, and R. Yang, Biotechnol, Adv.; 15, 43-58., (1997).

[24] J. Wang, From DNA biosensors to gene chips, Nucleic Acids.

[25] Research; vol. 28, No. 16, 3011-1016, (2000).

[26] K.K. Jain, . Nanotechnology in clinical laboratory diagnostics, Clinica Chimica Acta; 358, 37–54 (2005).

DOI: 10.1016/j.cccn.2005.03.014

[27] W. H De Jong, and J.A. Paul Borm, Drug delivery and nanoparticles: Applications and hazards, Int J Nanomedicine. 2008 une; 3(2): 133–149. Published online 2008 June.